Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
samedi, octobre 31
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Aura Biosciences Inc
AURA
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$6.14
-0.16
-2.46%
Dern. MÀJ: Oct 30, 4:00 PM
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Aura Biosciences Financials
Aura Biosciences (AURA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Aura Biosciences Q2 EPS $(0.48) Misses $(0.38) Estimate
Aura Biosciences (NASDAQ:AURA) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.38) by 29.73 percent. This is a 2.13 percent decrease over losses of $(0.47) per share
Benzinga Newsdesk
PRO
Aura Biosciences Q1 EPS $(0.50) Misses $(0.39) Estimate
Aura Biosciences (NASDAQ:AURA) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.39) by 28.21 percent. This is a 9.09 percent increase over losses of $(0.55) per share from
Benzinga Newsdesk
PRO
Aura Biosciences Q4 EPS $(0.37) Beats $(0.45) Estimate
Aura Biosciences (NASDAQ:AURA) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.45) by 17.78 percent. This is a 28.85 percent increase over losses of $(0.52) per share from
Benzinga Newsdesk
PRO
Aura Biosciences Q3 EPS $(0.40) Beats $(0.47) Estimate
Aura Biosciences (NASDAQ:AURA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.47) by 14.53 percent. This is a 4.76 percent increase over losses of $(0.42) per share from
Benzinga Newsdesk
PRO
Aura Biosciences Q2 EPS $(0.47) Beats $(0.49) Estimate
Benzinga Newsdesk
PRO
As Of March 31, 2025, Aura Biosciences Had Cash And Cash Equivalents And Marketable Securities Of $128M, Sufficient To Fund Its Operations Into 2H Of 2026
Benzinga Newsdesk
